Sign In
Last checked at 
8 Nov 2018 07:00
Renalytix AI plc
("Renalytix" or the "Company")
Director / PDMR shareholding
Renalytix AI plc (AIM: RENX), a developer of artificial intelligence ("AI") enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares"), at a price of 120 pence per Ordinary Share:
|
|
|
| Number of Ordinary Shares bought | Resultant Interest in Ordinary Shares | Resultant Interest in Ordinary Shares (%) |
|
James McCullough | Chief Executive Officer |
|
| 16,150 |
2,870,110 | 5.33 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
a)
| Name
| James R. McCullough | |||
2
| Reason for the notification
| ||||
a)
| Position/status
| Chief Executive Officer | |||
b)
| Initial notification /Amendment
| Initial Notification | |||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
a)
| Name
| Renalytix AI plc | |||
b)
| LEI
| 213800NTOH3FK3WER551 | |||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
a)
| Description of the financial instrument, type of instrument | Ordinary shares of 0.25 pence each | |||
|
| ||||
Identification code | GB00BYWL4Y04 | ||||
|
| ||||
b)
| Nature of the transaction
| Purchase of Ordinary Shares | |||
c)
| Price(s) and volume(s) |
|
|
|
|
|
| Price(s) | Volume(s) |
| |
|
| 120 pence | 16,150 |
| |
|
|
|
|
| |
d)
| Aggregated information | n/a | |||
|
| ||||
- Aggregated volume |
| ||||
|
| ||||
- Price |
| ||||
|
| ||||
e)
| Date of the transaction
| 06 November 2018 | |||
f)
| Place of the transaction
| London Stock Exchange | |||
For further information, please contact:
Renalytix AI plc | www.renalytixai.com | |
James McCullough, CEO | Via Walbrook PR or Tel: +1 646 397 3970
| |
|
| |
N+1 Singer (Nominated Adviser & Broker) | Tel: 020 7496 3000 | |
Aubrey Powell / James White / George Tzimas (Corporate Finance)Tom Salvesen / Ross Penney (Corporate Broking) |
| |
|
| |
|
| |
|
| |
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 | |
Follow the stocks
